Elanco Gains Market Share as Year-Round Tick and Itch Season Expands
Event summary
- Elanco's U.S. Pet Health business is on track for high-single to low-double digit growth in the second half of 2026.
- Price gains accelerated quarter-to-date (July and August) compared to Q2.
- Elanco's market share increased in Q2 across dermatology, parasiticides, osteoarthritis pain, and vaccines.
- Zenrelia gained 10 share points in Europe in the first half of 2026.
- Vet home delivery sales grew nearly twice as fast as in-clinic sales in Q2.
The big picture
Elanco is capitalizing on the shift toward year-round 'tick and itch season' driven by changing weather patterns. The company's innovative portfolio and omnichannel strategy are driving market share gains and price acceleration in the $18 billion global pet health market. The trend of milder winters and warmer springs is creating a durable demand for Elanco's products, positioning the company for long-term growth.
What we're watching
- Market Seasonality
- Whether Elanco can sustain its momentum as the U.S. OTC parasiticide market shifts to a more balanced seasonal distribution.
- Compliance Trends
- The pace at which home delivery and auto-ship programs drive compliance improvements.
- International Expansion
- How Zenrelia's success in Europe will translate to other international markets.
Related topics